Stan Wang, Thymmune Therapeutics CEO
September 29, 2023 04:34 AM EDTUpdated September 30, 12:00 AM
Startups

Stem cell start­up Thym­mune lands $37M from Biden's ARPA-H for im­mune-re­ju­ve­nat­ing ther­a­pies

Ryan Cross

Senior Science Correspondent

The Biden ad­min­is­tra­tion is award­ing up to $37 mil­lion to Thym­mune Ther­a­peu­tics, the Ad­vanced Re­search Projects Agency for Health (ARPA-H)

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times